People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Outcome of the IndiTreat clinical trial (TICC) is published by ASCO prior to its Annual Meeting in June 2021.
Redeye is the company’s Certified Adviser.
Phone: +46 8 121 576 90
2cureX – Bolagsbeskrivning
Redeye Growth Day 2021, Stockholm
Interim Report Q2 2021
View previous reports
Interim Report Q3 2021
Year-End Report 2021
IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.